Literature DB >> 292456

Studies on the mechanism of action of hexamethylene bisacetamide, a potent inducer of erythroleukemic differentiation.

R C Reuben.   

Abstract

Hexamethylene bisacetamide (diacetyldiamino hexane) is a potent inducer of erythroid differentiation in murine erythroleukemia cells. Hexamethylene bisacetamide and the closely related pentamethylene bisacetamide were synthesized with radioactive labels in various portions of the molecule and the uptake, metabolism, and intracellular distribution determined. Bisacetamides are taken up by the cell; an intracellular concentration equal to the extracellular concentration is achieved by 6-8 h. Commitment to differentiation is not detected until at least 10 h after equilibration. Both uptake and commitment to differentiate are concentration and temperature dependent. The majority of the compound is deacetylated upon cell entry and the acetate portion incorporated nonspecifically into lipid and protein. Acetate competes with the incorporation of hexamethylene bisacetamide into protein and lipid, but does not affect inducing activity. The diamine portion of the molecule is detected only in the cytoplasm, in a trichloroacetic acid-soluble and acetylated form, whereas the acetate moiety is detected in both cytoplasm and nucleus and in both a trichloroacetic acid-soluble and insoluble form. The cellular uptake of diamines and bisacetamides (acetylated diamines) are similar, but acetylation of the diamine greatly increases inducing activity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 292456     DOI: 10.1016/0304-4165(79)90339-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Effects of hexamethylene bisacetamide on alpha-fetoprotein, albumin, and transferrin production by two rat hepatoma cell lines.

Authors:  E H Hughes; H A Schut; S S Thorgeirsson
Journal:  In Vitro       Date:  1982-02

2.  Erythroid differentiation and commitment in rat erythroleukemia cells with hypertonic culture conditions.

Authors:  Y Yamaguchi; N Kluge; W Ostertag; M Furusawa
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

3.  The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.

Authors:  B A Conley; G F Sewack; M J Egorin; B Subramanyam; J G Page; C K Grieshaber
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Approaches to optimal dosing of hexamethylene bisacetamide.

Authors:  B A Conley; M J Egorin; V Sinibaldi; G Sewack; C Kloc; L Roberts; E G Zuhowski; A Forrest; D A Van Echo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Catabolites produced by the deacetylation of hexamethylenebisacetamide play a key role in murine erythroleukaemic-cell differentiation.

Authors:  E Meilhoc; M J Moutin; H B Osborne
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

6.  Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.

Authors:  B A Conley; M J Egorin; E G Zuhowski; V J Sinibaldi; D E Peterson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Chemical inducers of differentiation in a long-term renal cell line.

Authors:  J E Lever
Journal:  Environ Health Perspect       Date:  1989-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.